Preparation of new thermostable COVID-19 vaccine for human clinical trials

The new thermostable COVID-19 vaccine has provided strong preclinical results. The vaccine can remain stable at approximately 37 ° C (98 ° F) for up to 30 days, and researchers aim to begin clinical trials in humans later this year.

One particular challenge in effectively distributing the COVID-19 vaccine worldwide is the need to keep most vaccines cold. For example, Pfizer and BioNTech mRNA vaccines are notorious for requiring ultra-low temperature storage of -80ºC to -60ºC (-112ºF to -76ºF), making remote delivery very difficult.

Recent research from Pfizer It is safe to modify these temperature guidelines and find a normal freezer temperature of -25 ° C to -15 ° C (-13 ° F to 5 ° F) for at least two weeks. However, refrigerated supply lines still make it difficult to distribute vaccines widely.

“Heat stability or” warm vaccines “are important for remote areas and resource-constrained areas in very hot climates, where reliable refrigeration supply chains are lacking, such as in the Australian outback and local communities in the Indo-Pacific region. “Australia citizen Rob Grenfell said. Scientific institution, CSIRO.

The new vaccine was developed by biotechnology startup Mynvax in collaboration with the Indian Institute of Science.Report in the journal ACS infection, Researchers have found that the vaccine produces potent neutralizing antibodies against SARS-CoV-2 in mouse and guinea pig models.

“Our data show that all formulations of Mynvax tested provide antibodies capable of consistent and effective neutralization of the alpha, beta, gamma, and delta SARS-CoV-2 variants of concern. “, Says SS Vasan, co-author of the new study.

This thermostable vaccine formulation has been found to be very stable at warm temperatures. It was valid for a month at a temperature of 37 ° C (98 ° F) and remained stable at a boiling temperature of 100 ° C (212 ° F) for up to 90 minutes.

These promising preclinical results pave the way for human trials to begin later this year. Researchers hope that a thermostable COVID-19 vaccine that is effective against the new SARS-CoV-2 mutant will help deliver the vaccine to remote communities.

New research published in journal ACS infection..

Source: CSIRO Preparation of new thermostable COVID-19 vaccine for human clinical trials

Back to top button